Discovery of a Novel Public Antibody Lineage Correlated With Inactivated SARS‐CoV‐2 Vaccine and the Resultant Neutralization Activity
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.70073 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Jing Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, China. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, Antibodies, Viral, COVID-19 Vaccines, SARS-CoV-2. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: This work was supported by Key Project of Science and Technology Department of Anhui Province "New SERS technology for rapid detection of SARS-CoV-2 activity a….
Abstract (Originalsprache)
While the SARS‐CoV‐2 vaccine offers 70%–95% protection effectiveness against Coronavirus disease 2019 (COVID‐19), a portion of recipients do not produce adequate protective immune responses, particularly, neutralizing antibodies (nAbs). Previous studies of COVID‐19 patients have identified several public antibody lineages, such as IGHV3‐30, IGHV3‐33, IGHV3‐53, IGHV1‐58, and IGHV1‐24. However, it remains unclear how these public antibodies evolve during vaccination or whether there are any special antibody lineages correlated with SARS‐CoV‐2 vaccination. In this study, through a combination of single B cell sequencing and next‐generation sequencing analysis, we systemically studied the dynamic changes of antibody lineages derived from different B cell germlines in their sequence, frequency, and neutralization ability in different vaccinees before and after receiving inactivated SARS‐CoV‐2 vaccines. Our findings indicate that the frequency of antibodies derived from the IGHV4‐34 lineage increased in most individuals after vaccination, and the higher frequency of the antibody usually resulted in stronger binding affinity. Additionally, the ratio of IGHV4‐34 derived antibodies, when compared with other public antibodies, more strongly correlated with the neutralization activity of immune sera from vaccinees. Taken together, these results suggest that IGHV4‐34 is a novel vaccine‐elicited public nAb lineage that plays a crucial role in immune response following inactivated COVID‐19 vaccination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, China.
- Anhui Provincial Center for Disease Control and Prevention, Hefei, China.
- Hefei Infectious Disease Hospital, Hefei, China.
ORCID-Profile: Chenchen Wang
Förderung
- This work was supported by Key Project of Science and Technology Department of Anhui Province "New SERS technology for rapid detection of SARS-CoV-2 activity a…
Zitieren
APA
Wang, J., Ni, S., Chen, Q., Wang, C., Liu, H., Huang, L., Nasir, M. W., Wang, W., Zhang, X., Wu, J., Liu, Z., Wu, J., Zhang, L., & Gao, Y. (2024). Discovery of a Novel Public Antibody Lineage Correlated With Inactivated SARS‐CoV‐2 Vaccine and the Resultant Neutralization Activity. Journal of Medical Virology. https://doi.org/10.1002/jmv.70073
Vancouver
Wang J, Ni S, Chen Q, Wang C, Liu H, Huang L, et al. Discovery of a Novel Public Antibody Lineage Correlated With Inactivated SARS‐CoV‐2 Vaccine and the Resultant Neutralization Activity. Journal of Medical Virology. 2024. doi:10.1002/jmv.70073
BibTeX
@article{Wang2024,
author = {Wang, Jing and Ni, Shuangshuang and Chen, QianQian and Wang, Chenchen and Liu, Hao and Huang, Lina and Nasir, Muhammad Waqas and Wang, Wei and Zhang, Xiangyu and Wu, Jianjun and Liu, Zhirong and Wu, Jiabing and Zhang, Liangmin and Gao, Yong},
title = {Discovery of a Novel Public Antibody Lineage Correlated With Inactivated SARS‐CoV‐2 Vaccine and the Resultant Neutralization Activity},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.70073}
}
EUVIMED